Epsilon M&A Deal Report - Laboratoire de la Mer SASU

Transaction Multiples for the Valuation of Private Companies

Omega Pharma > Laboratoire de la Mer SASU

Announced Date : 29 September 2010

Type : Exit ,Acquisition of Majority Stake

Deal Value : Yes

Acquirer : Omega Pharma

Target: Laboratoire de la Mer SASU

Target Country: France

Sector of activity : Health, Pharmaceuticals & Biotechnology

Business Description :

> Laboratoire de la Mer develops and markets all-natural OTC health products that target the &lsq ...

No EMAT : 22900

Transaction multiples available

	EV/Sales	EV/Gross Profit	EV/EBITDA	EV/EBIT	Eq/PBT	P/E	Price to Book
Historic
Current

: Multiple available

n.s : Multiple calculated, but not significant

Rating **

Source: Epsilon Research / EMAT

Comparable Transactions

Number of EMAT Reports : (Health, Pharmaceuticals & Biotechnology) = 1245

Example of comparable transactions on EMAT (same sub-sector):

Date	Acquirer	Target	Country	Multiples	See details
11/02/2011	Private Group led by CIC LBO Partners	Assistances Médicales Spécialisées (AMS)	France	*
23/12/2008	Eckert & Ziegler Strahlen Und Medizintechnik (EZAG)	Nuclitec	Germany	**

Source: Epsilon Research / EMAT

View Report

This report is accessible on EMAT, the reference database for private company acquisition multiples

Example of EMAT Report : click here

View Complete Report

About Epsilon Research

Epsilon Research is an independent research and financial analysis bureau, and the reference source of transaction multiples for the valuation of private companies through its EMAT database.

Sectors covered by our analysts

Studies & indices published by Epsilon Research Register to receive (free) publications updates

EMAT Report

Each EMAT Report includes the detailed analysis of the transaction: deal rationale and structure, target business lines and financials (restated), valuation multiples (calculation and analysis).

Subscribe to EMAT database